THE SCIENCE
Our Approach
NextPoint is launching a new world of precision therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis. Our team of proven drug developers is advancing an antibody-drug-conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint inhibitor. Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed modality, so that we can deliver first-in-class therapies to a broad range of cancer patients with B7-H7 upregulation including those who do not benefit from currently approved therapies such as PD-1/L1 inhibitors.
EXCITING NEW TARGET
Our Founders Independently Discovered a Novel B7 Receptor Checkpoint Axis
- Clinical opportunities independent of established immunotherapies
- Broad pipeline maximizing opportunities for immunomodulation and tumor-targeting through B7-H7
- All first-in-class assets with a strong IP position
STRATEGY
Targeting A Novel Immuno-Oncology Checkpoint and Tumor-Associated Antigen
Our Pipeline
Broad pipeline maximizing opportunities for immunomodulation and tumor-targeting by exploiting all aspects of the B7-H7 axis
|
Discovery
|
Ab Development
|
DC Selection
|
Manufacturing
|
GLPtox/IND
|
Clinical
|
|---|
|
Discovery
|
Clinical
|
|---|
ABOUT US
One pathway, many possibilities
First-in-class opportunity
NextPoint is launching a new world of immuno-oncology and tumor-targeting through its leading scientific work on the novel B7-H7/HHLA2 pathway.
Attractive Monotherapies
Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients including those who do not benefit from PD-1/L1 inhibitors.
Precision oncology
OUR TEAM
World-class team
We are building a world-class team to help us realize the full potential of our scientific founders’ exciting discoveries and to shape the future of immuno-oncology and tumor-targeting
Ivan Cheung, MBA
Chief Executive Officer
Paul Conrad, PhD, MBA
Chief Business Officer
Leena Gandhi, MD, PhD
Chief Medical Officer
Tatiana Novobrantseva, PhD
Chief Scientific Officer
Gordon Freeman, PhD
Dana-Farber Cancer Institute
XingXing Zang, PhD
Albert Einstein College of Medicine
QUOTES FROM
OUR FOUNDERS
The combined expertise and research of Gordon Freeman, PhD (Dana-Farber Cancer Institute) and XingXing Zang, PhD (Albert Einstein College of Medicine) form the basis of NextPoint Therapeutics. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology and tumor targeting.
I’m fascinated by the HHLA2 pathway because it looks like an alternative, non-redundant pathway than PD-L1 for turning off the anti-tumor immune response. I want Nextpoint to test whether it can be as effective as blocking PD-L1. Can we catch lightning twice?
- Gordon Freeman, PhD
From the discovery of the HHLA2 immune checkpoint pathway in 2013 to the first-in-class clinical trial targeting this pathway in 2023, NextPoint Therapeutics is revolutionizing the landscape of immuno-oncology and offering new hope for a broad spectrum of human cancer patients unresponsive to existing PD-1/L1 inhibitors.
- XingXing Zang, PhD
Investors & partners
We’re proud to collaborate with visionary investors and esteemed partners who share our commitment to advancing the field of precision immuno-oncology and tumor-targeting therapeutics
Careers
Join us at NextPoint Therapeutics and be part of a team pioneering immuno-oncology advancements
Clinical Development Leader
Check out the open positions on our LinkedIn
Send us an email with your resume
